Compare IDEXX Laboratories, Inc. (IDXX) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Visa Inc — how do they compare? IDEXX Laboratories, Inc. trades at $570.95 (market cap $46.22B), while Visa Inc trades at $358.86 (market cap $671.74B). The key difference: Visa Inc is far larger — about 14.5× IDEXX Laboratories, Inc.'s market cap, and Visa Inc pays a 0.74% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | V | |
|---|---|---|
Market Cap | $46.22B | $671.74B |
Sector | Health | Financials |
52-Week High | $766.68 | $370.47 |
52-Week Low | $526.44 | $295.52 |
Enterprise Value | $47.12B | $682.32B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Visa (V) trades at $358.92, down 0.66% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth from $40B in 2025 to a projected $44.5B in 2026. Analyst consensus is overwhelmingly bullish, with an 85.48% buy rating and a $426.31 price target, suggesting 19% upside. Recent news highlights Visa's AI initiatives, such as Intelligent Commerce Connect, to enhance payment efficiency.
Visa's outlook remains positive due to consistent earnings outperformance, high profit margins, and strategic AI adoption. Risks include rising fintech competition and regulatory pressures. The stock presents a long-term growth opportunity, supported by solid fundamentals and institutional confidence, though investors should monitor competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
